EPCAM and neoplasm: Using MT110, a bi-specific antibody to EpCAM and human CD3 [84], this group was able to eliminate primary human colorectal tumors in a xenograft model, as well as xenografts generated from the HT29 CRC cell line by inducing tumor-specific T-cell cytotoxicity while avoiding apparent toxicity to the host animal [85].